Home・Lista de Ações・DexCom Inc

DexCom Inc

Fechado

SetorSaúde

86.95 -0.29

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

85.87

Máximo

87.73

Indicadores-chave
By Trading Economics
Rendimento	50M 249M
Vendas	117M 1.3B
P/E Médio do Setor	34.51 68.51
EPS	0.7
Margem de lucro	19.039
Funcionários	11,000
EBITDA	52M 389M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+3.68% upside

Dividendos
By Acuity
Próximos Ganhos	29 de out. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	4.6B 33B
Abertura anterior	87.24
Fecho anterior	86.95

Sentimento de Notícias

By Acuity

21%

79%

64 / 340 Ranking em Healthcare

DexCom Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

4 de ago. de 2026, 19:56 UTC

Dexcom Inc. shares are lower today, pulling back after reaching a session high. The broader market benefits from a significant decline in crude oil prices.

3 de ago. de 2026, 20:02 UTC

News

Social Media

Dexcom Inc. shares are higher following strong Q2 results and raised revenue guidance to $5.22 billion. Canaccord increased its price target to $90.

31 de jul. de 2026, 20:04 UTC

News

Social Media

Dexcom Inc. shares are higher following analyst upgrades and strong earnings, with second-quarter revenue of $1.31 billion exceeding expectations and guidance raised to $5.22 billion.

30 de jul. de 2026, 23:51 UTC

News

Social Media

Dexcom reported second-quarter revenue of $1.308 billion and adjusted EPS of $0.70, raising its fiscal year 2026 revenue guidance, with shares trading higher in after-market hours.

29 de jul. de 2026, 23:41 UTC

Dexcom Inc is trading higher in after-market hours, supported by overall market strength. The asset remains above its 20-day moving average.

28 de jul. de 2026, 20:06 UTC

News

Dexcom shares rise after UBS initiated coverage with a Buy rating. The stock is advancing since Monday's close of $73.37 amid positive sentiment in the Health Care Equipment sector.

27 de jul. de 2026, 19:06 UTC

News

Dexcom Inc. gains Health Canada approval for its Dexcom G7 continuous glucose monitoring system, boosting marketability and user adoption amid positive analyst sentiment.

24 de jul. de 2026, 15:22 UTC

Dexcom Inc's shares are higher today, driven by gains in the Health Care Equipment sub-sector. No specific company news was identified for the movement.

22 de jul. de 2026, 20:01 UTC

Dexcom Inc. shares are lower today, continuing a decline since Tuesday. Earlier, the stock briefly rose before pulling back.

21 de jul. de 2026, 19:26 UTC

Dexcom Inc is trading lower, continuing a trend of three consecutive declines. The stock reached a session low earlier today before a slight recovery.

20 de jul. de 2026, 19:22 UTC

Dexcom Inc shares are lower amid broader market declines and rising Treasury yields. The stock remains near the upper end of its one-month trading range.

Comparação entre Pares

Variação de preço

DexCom Inc Previsão

Preço-alvo

By TipRanks

3.68% parte superior

Previsão para 12 meses

Média 90.52 USD 3.68%

Máximo 112 USD

Mínimo 64 USD

Com base em 23 analistas de Wall Street que oferecem metas de preço de 12 meses para DexCom Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

23 ratings

Comprar

Manter

Vender

Com base em 23 analistas que deram avaliações de ações para DexCom Inc - Dist nos últimos 3 meses.

Sentimento

By Acuity

64 / 340 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre DexCom Inc

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.